The CEO of Neurocrine is Exercising Options

Today it was reported that the CEO of Neurocrine (NBIXResearch Report), Kevin Charles Gorman, exercised options to buy 3,031 NBIX shares at $32.99 a share, for a total transaction value of $99.99K.

See today’s analyst top recommended stocks >>

Based on Neurocrine’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $184 million and quarterly net profit of $51.34 million. In comparison, last year the company earned revenue of $96.91 million and had a GAAP net loss of $5.91 million. The company has a one-year high of $126.98 and a one-year low of $64.72. Currently, Neurocrine has an average volume of 841.90K.

Eight different firms, including Cowen & Co. and Credit Suisse, currently also have a Buy rating on the stock.

Kevin Charles Gorman’s trades have generated a 33.5% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders.